Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
出版年份 2022 全文链接
标题
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
作者
关键词
-
出版物
CIRCULATION
Volume 146, Issue 15, Pages 1109-1119
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2022-08-29
DOI
10.1161/circulationaha.122.061620
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
- (2022) Lorenz Räber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
- (2022) Stephen J. Nicholls et al. JACC-Cardiovascular Imaging
- Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials
- (2022) Belinda Schludi et al. Journal of Clinical Lipidology
- Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
- (2021) et al. EUROPEAN HEART JOURNAL
- Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization
- (2020) Kazuma Oyama et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
- (2019) Scott M. Grundy et al. CIRCULATION
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
- (2016) Marc S. Sabatine et al. AMERICAN HEART JOURNAL
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
- (2013) Heart Protection Study Collaborative Group LANCET
- The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK
- (2011) Peter S. Sever et al. EUROPEAN HEART JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now